

Molecular Basis of the Isoform-specific Ligand-binding Affinity of Inositol 1,4,5-Trisphosphate Receptors*[§]

Received for publication, October 18, 2006, and in revised form, February 1, 2007 Published, JBC Papers in Press, February 27, 2007, DOI 10.1074/jbc.M609833200

Miwako Iwai[‡], Takayuki Michikawa^{‡§¶1}, Ivan Bosanac^{||}, Mitsuhiro Ikura^{||}, and Katsuhiko Mikoshiba^{‡§¶2}

From the [‡]Division of Molecular Neurobiology, Department of Basic Medical Sciences, Institute of Medical Science, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan, the [§]Laboratory for Developmental Neurobiology, Brain Science Institute, RIKEN, Saitama 351-0198, Japan, the [¶]Calcium Oscillation Project, International Cooperative Research Project-Solution Oriented Research for Science and Technology, Japan Science and Technology Agency, Saitama 332-0012, Japan, and the ^{||}Division of Signaling Biology, Ontario Cancer Institute, Department of Medical Biophysics, University of Toronto, Toronto, Ontario M5G 1L7, Canada

Three isoforms of the inositol 1,4,5-trisphosphate (IP₃) receptor (IP₃R), IP₃R1, IP₃R2, and IP₃R3, have different IP₃-binding affinities and cooperativities. Here we report that the amino-terminal 604 residues of three mouse IP₃R types exhibited K_d values of 49.5 ± 10.5 , 14.0 ± 3.5 , and 163.0 ± 44.4 nM, which are close to the intrinsic IP₃-binding affinity previously estimated from the analysis of full-length IP₃Rs. In contrast, residues 224–604 of IP₃R1 and IP₃R2 and residues 225–604 of IP₃R3, which contain the IP₃-binding core domain but not the suppressor domain, displayed an almost identical IP₃-binding affinity with a K_d value of ~ 2 nM. Addition of 100-fold excess of the suppressor domain did not alter the IP₃-binding affinity of the IP₃-binding core domain. Artificial chimeric proteins in which the suppressor domain was fused to the IP₃-binding core domain from different isoforms exhibited IP₃-binding affinity significantly different from those of the proteins composed of the native combination of the suppressor domain and the IP₃-binding core domain. Systematic mutagenesis analyses showed that amino acid residues critical for type-3 receptor-specific IP₃-binding affinity are involved in Glu-39, Ala-41, Asp-46, Met-127, Ala-154, Thr-155, Leu-162, Trp-168, Asn-173, Asn-176, and Val-179. These results indicate that the IP₃-binding affinity of IP₃Rs is specifically tuned through the intramolecular attenuation of IP₃-binding affinity of the IP₃-binding core domain by the amino-terminal suppressor domain. Moreover, the functional diversity in ligand sensitivity among IP₃R isoforms originates from at least the structural difference identified on the suppressor domain.

The inositol 1,4,5-trisphosphate (IP₃)³ receptors (IP₃Rs) function as IP₃-gated Ca²⁺ release channels located on intra-

cellular Ca²⁺ stores, such as the endoplasmic reticulum (1). Mammalian IP₃R family consists of three isoforms (IP₃R1, IP₃R2, and IP₃R3), and they form homotetrameric or heterotetrameric channels (2). There is evidence of a functional difference among the three isoforms of IP₃R in terms of their IP₃ sensitivity (3–5) and cooperativity with respect to IP₃ binding (5). The intrinsic association constants of mouse IP₃R1, IP₃R2, and IP₃R3 expressed in Sf9 cells are estimated to be 3.5×10^7 , 1.7×10^8 , and 3.4×10^6 (M⁻¹), respectively (5). IP₃R2 exhibits both negative and positive cooperativity, whereas IP₃R3 exhibits negative IP₃ binding cooperativity (5). This diversity of responsiveness to IP₃ observed among the three IP₃R isoforms may contribute to the generation of the different degree of IP₃ sensitivity of the Ca²⁺ store. The molecular basis of the isoform-specific IP₃-binding affinity, however, is not well understood.

The IP₃-binding domain of IP₃R1 is composed of two functional domains, the amino-terminal suppressor domain and the carboxyl-terminal IP₃-binding core domain (6). The IP₃-binding core domain is the minimum region required for specific IP₃ binding and is mapped within residues 226–578 of mouse IP₃R1, a polypeptide of 2749 residues (6). The amino-terminal 225 amino acid residues of IP₃R1 function as the suppressor for IP₃ binding, and deletion of these residues results in significant enhancement of IP₃ binding (6). The atomic resolution structures of both the suppressor domain (7) and the IP₃-binding core domain (8) of mouse IP₃R1 were solved by x-ray crystallography to 1.8- and 2.2-Å resolution, respectively. The IP₃-binding core domain comprises two asymmetric domains, the β -domain and α -domain. A highly positive-charged pocket is created at the interface of these two domains to which an IP₃ molecule binds. The 11 amino acid residues in the IP₃-binding core domain of IP₃R1 are responsible for the coordination of IP₃ (8), and all of them except Gly-268 are conserved in other isoforms. The suppressor domain contains a β -trefoil fold and a helix-turn-helix structure inserted between two β -strands of the β -trefoil fold (7). The conserved 7 amino acid residues, which are clustered on one side of the suppressor domain, were found to be critical for the suppression of IP₃ binding (7). These structural and functional analyses of the IP₃-binding domain have been carried out mainly using the type-1 isoform, and the suppression ability of the amino-terminal regions of IP₃R2 and IP₃R3 has not been well characterized.

* This work was supported by the Ministry of Education, Culture, Sports, Science and Technology of Japan (Grants 17017013 and 17570128 to T. M. and Grant 15100006 to K. M.), by the Heart and Stroke Foundation of Canada (to M. I.), and by the Moritani Scholarship Foundation (to T. M.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

[§] The on-line version of this article (available at <http://www.jbc.org>) contains supplemental Tables S1–S3, Figs. S1–S3, and an additional reference.

¹ To whom correspondence may be addressed. Tel.: 81-3-5449-5317; Fax: 81-3-5449-5420; E-mail: takamich@ims.u-tokyo.ac.jp.

² To whom correspondence may be addressed. Tel.: 81-3-5449-5316; Fax: 81-3-5449-5420; E-mail: mikoshiba@ims.u-tokyo.ac.jp.

³ The abbreviations used are: IP₃, inositol 1,4,5-trisphosphate; IP₃R, IP₃ receptor.

Isoform-specific IP₃-binding Affinity of IP₃Rs




FIGURE 1. Comparison of IP₃-binding affinity of the amino-terminal 604 residues among the three IP₃R isoforms. *A*, SDS-PAGE analysis of T604s. Purified proteins (1 μ g each) of T604_{m1} (lane 1), T604_{m2} (lane 2), and T604_{m3} (lane 3) were separated on 7.5% SDS-PAGE followed by Coomassie Brilliant Blue R-250 staining. Arrowheads indicate T604 proteins. Molecular size markers are shown on the left ($\times 10^3$). *B*, equilibrium IP₃-binding activity of the IP₃-binding domains of the three IP₃R isoforms. Values are averages of 3 (T604_{m1}, circle), 3 (T604_{m2}, triangle), and 9 (T604_{m3}, square) measurements. Error bars correspond to the standard deviation. *C*, comparison between the apparent dissociation constants of T604 and the intrinsic dissociation constants estimated from the measurements using full-length IP₃Rs expressed in Sf9 cells (5). Circle, IP₃R1; triangle, IP₃R2; and square, IP₃R3. Error bars correspond to the standard deviation.

In the present study, we analyzed the IP₃-binding affinity of the IP₃-binding domain of three isoforms and found that the intramolecular suppression of IP₃ binding specifically tunes the IP₃-binding affinity of IP₃R isoforms. Systematic analyses of chimeric mutants and site-directed mutants created based on the three-dimensional structures of the suppressor domain provide us with a novel insight into the

structural basis of the isoform-specific IP₃-binding affinity of the three IP₃R types.

EXPERIMENTAL PROCEDURES

Gene Construction—Plasmids carrying the amino-terminal 604 amino acid residues of mouse IP₃R1, IP₃R2, and IP₃R3 (T604_{m1}, T604_{m2}, and T604_{m3}, respectively) were constructed as follows. The 1.8-kbp fragments of the three IP₃R genes were amplified with the PCR method from pBact-STneoB-C1, pBluescriptII-C2, and pBact-STneoB-C3 (5), with three pairs of primers, P1/P4, P2/P5, and P3/P4 (supplemental Table S1), respectively. The fragments were digested with NdeI and EcoRI and were subcloned into the modified pRSET-A (Invitrogen), in which the hexa-histidine (His₆) tag coding region was removed, to generate pRSET-T604_{m1}, pRSET-T604_{m2}, and pRSET-T604_{m3}, respectively. To express amino acid residues 224–604 of IP₃R2 and 225–604 of IP₃R3 (supplemental Fig. S1), plasmids were constructed as follows. The 1.1-kbp fragments were amplified from pBluescriptII-C2 and pBact-STneoB-C3 with pairs of primers, P6/P5, and P7/P4 (supplemental Table S1), respectively. The fragments were digested with NdeI and EcoRI and were subcloned into the His₆ tag-removed pRSET-A to generate pRSET-(224–604)_{m2} and pRSET-(225–604)_{m3}, respectively. For the expression of residues 224–604 of mouse IP₃R1, pET-D-(1–223)/T604 (9) was used. For the expression of the His₆-tagged suppressor domain (residues 2–223) of mouse IP₃R1 (supplemental Fig. S1), pET23a-T7-IP₃R_{sup}-6His (7) was used. Plasmids carrying chimeric proteins, in which the suppressor domains were fused to the IP₃-binding core domain from different isoforms (supplemental Fig. S1), were constructed using the technique of splicing by overlap extension with PCR (10) and primers, P1, P3–5, P8, and P10–18 (supplemental Table S1). The combination of templates and primers used is summarized in supplemental Table S2. Mixtures of two DNA fragments separately produced in the first PCRs were used as templates for the second PCR (supplemental Table S2). The products of the second PCR were digested with NdeI and EcoRI and were subcloned into the His₆ tag-removed pRSET-A to generate pRSET-(1–223)_{m2}-(224–604)_{m1}, pRSET-(1–224)_{m3}-(224–604)_{m1}, pRSET-(1–223)_{m1}-(224–604)_{m2}, pRSET-(1–224)_{m3}-(224–604)_{m2}, pRSET-(1–223)_{m1}-(225–604)_{m3}, and pRSET-(1–223)_{m2}-(225–604)_{m3}, respectively.

Site-directed mutagenesis within the suppressor domain of T604_{m3} or (1–223)_{m1}-(225–604)_{m3} (supplemental Fig. S2) to engineer systematic chimeric proteins as summarized in supplemental Fig. S2 was performed with a Quick Change site-directed mutagenesis kit (Stratagene) and primers containing the appropriate substitution (M1–M13, supplemental Table S3). Multiple mutants were generated by sequential mutagenesis. Only sense primers used for the site-directed mutagenesis are shown in supplemental Table S3. Substitution of amino acid residues 61–122 of T604_{m3} with amino acid residues 62–121 of T604_{m1} was carried out using the technique of splicing by overlap extension with PCR (supplemental Table S2) and primers P3, P19, P20, and P21 (supplemental Table S1). The product of the second PCR was digested with NdeI, and the NdeI fragment (0.4 kbp) was replaced with the NdeI fragment (0.4 kbp) of pRSET-T604_{m3}. The nucleotide sequences of all of PCR prod-

Isoform-specific IP₃-binding Affinity of IP₃Rs




FIGURE 2. Comparison of IP₃-binding affinity of the IP₃-binding core domain among the three IP₃R isoforms. *A*, SDS-PAGE analysis. Purified proteins (0.75 μ g) of (224–604)_{m1} (lane 1), (224–604)_{m2} (lane 2), and (225–604)_{m3} (lane 3) were

ucts and site-directed mutants used in this study were confirmed by DNA sequencing with a 3130 Genetic analyzer (Applied Biosystems).

Expression and Purification of Recombinant Proteins—Recombinant proteins were expressed in *Escherichia coli* BL21-codonplus (Stratagene) as described previously (9). Protein purification was performed with a HiTrap heparin HP column (GE Healthcare) according to the method described previously (5). The His₆-tagged suppressor domain of mouse IP₃R1 (amino acid residues 2–223) was purified with a ProBond resin (Invitrogen) as described previously (5). Protein concentrations were determined with a protein assay kit (Bio-Rad) and bovine serum albumin as a standard.

IP₃ Binding Assay—An equilibrium IP₃ binding analysis of purified soluble proteins was performed as described previously (9), except for the reaction condition with a cytosol-like medium (110 mM KCl, 10 mM NaCl, 5 mM KH₂PO₄, and 50 mM Hepes-KOH, pH 7.4, at 4 °C). Purified protein (0.02–0.8 μ g) was incubated with 0.14–8.68 nM [³H]IP₃ (New England Nuclear/DuPont) and various concentrations of unlabeled IP₃ (Dojindo) in a binding buffer (cytosol-like medium containing 1 mM dithiothreitol and 0.5 mM EGTA). To avoid tracer depletion, the amount of the protein and the concentration of [³H]IP₃ were adjusted for each experiment. Nonspecific binding was measured in the binding buffer without adding the protein. Nonlinear regression of IP₃ binding data with the Hill-Langmuir equation,

$$F = \frac{[IP_3]}{K_d + [IP_3]} \quad (\text{Eq. 1})$$

where F is the fraction of the recombinant protein that binds IP₃, $[IP_3]$ is the concentration of IP₃, and K_d is the apparent dissociation constant, was performed with Igor Pro (version 4.04, Wavemetrics) software.

Modeling of the Suppressor Domain in IP₃R3—The structure of the IP₃R1 suppressor domain (residues 7–223) (7) was used for homology modeling of the suppressor domain structure of IP₃R3, residues 6–224. The sequence alignment between IP₃R1 and IP₃R3 was generated with ClustalW (11) and used for modeling with Modeller (12). Because the loop linking the two helices in the Arm sub-domain of IP₃R1 (residues 76–81) was not defined in the original structure, this portion of the suppressor domain was also modeled in the type-3 isoform. Thirty models were calculated and superimposed with Molmol (13) (root mean square deviation = 1.2 Å). Only the mean model is shown.

separated on 10% SDS-PAGE followed by Coomassie Brilliant Blue R-250 staining. *Arrowheads* indicate the proteins containing IP₃-binding core domains. Molecular size markers are shown on the *left* ($\times 10^3$). *B–D*, the relationship between normalized IP₃ binding and IP₃ concentrations applied. *Filled circles*: (224–604)_{m1} (*B*), (224–604)_{m2} (*C*), and (225–604)_{m3} (*D*). The IP₃-binding activity of T604s shown in Fig. 1*B* is plotted as *open circles* (*B*, T604_{m1}; *C*, T604_{m2}; and *D*, T604_{m3}). *E*, comparison of the apparent dissociation constants of (224–604)_{m1}, (224–604)_{m2}, and (225–604)_{m3}. Averages of three independent measurements are shown. *Error bars* correspond to the standard deviation. Statistical analysis was performed using one-way analysis of variance followed by a post-hoc comparison using Dunn's multiple comparison procedure. *N.S.*, not significant.

Isoform-specific IP₃-binding Affinity of IP₃Rs




FIGURE 3. Apparent dissociation constants of chimeric proteins in which the suppressor domain was fused to the IP₃-binding core domain from different isoforms. A–F, average values of the apparent dissociation constant of the proteins with natural combinations of the suppressor domain and the IP₃-binding core domain (open bar) and of the chimeric proteins (filled bar) are shown. The number of measurements is shown in parentheses. Error bars correspond to the standard deviation. Statistical analyses were performed using one-way analysis of variance or Kruskal-Wallis test followed by a post-hoc comparison using Turkey-Kramer, Scheffe's F, or Dunn's multiple comparison procedure. *, $p < 0.05$; **, $p < 0.01$; N.S., not significant.

RESULTS

Characterization of IP₃ Binding to the Amino-terminal 604 Residues of Three IP₃R Isoforms—Nontagged amino-terminal 604 amino acid residues of the three isoforms of mouse IP₃Rs, T604_{m1}, T604_{m2}, and T604_{m3} (supplemental Fig. S1), were expressed in *E. coli* and were purified on a HiTrap heparin HP column. Recombinant T604 proteins showed an apparent molecular mass of ~65 kDa (Fig. 1A). We measured the IP₃-binding activity of these purified proteins using ³H-labeled IP₃. Fig. 1B shows the relationship between the normalized amount of IP₃ bound to the purified proteins and the IP₃ concentration applied. Because the data of the three isoforms were well fitted with the Hill-Langmuir equation (see “Experimental Procedures”) and each protein possesses a single IP₃-binding site, IP₃ binding to the purified amino-terminal 604 amino acid residues

seemed to occur independently. The apparent dissociation constants of T604_{m1}, T604_{m2}, and T604_{m3} were estimated to be 49.5 ± 10.5 nM ($n = 3$), 14.0 ± 3.5 nM ($n = 3$), and 163.0 ± 44.4 nM ($n = 9$) (mean \pm S.D.), respectively. These values are well consistent with the intrinsic dissociation constants estimated from the analyses of homotetrameric IP₃R channels expressed in Sf9 cells under the same experimental condition (28.6 nM for IP₃R1, 5.9 nM for IP₃R2, and 294.0 nM for IP₃R3) (5) (Fig. 1C). These results suggest that the type-specific IP₃-binding affinity originates from the amino-terminal 604 amino acid residues of each IP₃R type.

Comparison of the IP₃-binding Affinity of the IP₃-binding Domain of Three Isoforms without the Suppressor Domain—The IP₃-binding domain of IP₃R1 is functionally divided into two parts: the amino-terminal suppressor domain and the carboxyl-terminal IP₃-binding core domain (6, 14). The IP₃-binding core domain has been defined as a minimum essential region for specific IP₃ binding, which resides within amino acid residues 226–578 of IP₃R1 (6). Because the amino acid residues 224–604 of mouse IP₃R1, designated as (224–604)_{m1} (supplemental Fig. S1B), are expressed well in *E. coli* (9), we used it for the measurement of the IP₃-binding affinity of the IP₃-binding domain without the suppressor domain. Supplemental Fig. S1A shows portions of the amino acid sequence alignments among the three mouse IP₃R iso-

forms. To compare the unsuppressed IP₃-binding affinity among the three isoforms, we purified the bacterially expressed (224–604)_{m1}, residues 224–604 of mouse IP₃R2 ((224–604)_{m2}), and the residues 225–604 of mouse IP₃R3 ((225–604)_{m3}) (Fig. 2A). We found that all of the IP₃ binding data of these proteins were well fitted with the Hill-Langmuir equation (Equation 1) (Fig. 2, B–D) with statistically indistinguishable apparent dissociation constants, 1.78 ± 0.63 nM ($n = 3$) for (224–604)_{m1}, 1.51 ± 0.01 nM ($n = 3$) for (224–604)_{m2}, and 2.04 ± 0.65 nM ($n = 3$) for (225–604)_{m3} (mean \pm S.D.) (Fig. 2E). These results indicate that the presence of the amino-terminal 223, 223, and 224 amino acid residues of mouse IP₃R1, IP₃R2, and IP₃R3 results in the suppression of IP₃ binding by 27.8-fold (Fig. 2B), 9.3-fold (Fig. 2C), and 81.1-fold (Fig. 2D), respectively. Moreover, the isoform-specific IP₃-binding affinity of the

native IP₃Rs reflects the different degree of the suppression of IP₃ binding by the suppressor domain of each isoform.

Mechanism of IP₃ Binding Suppression—To assess the mechanism for the suppression, we investigated the effect of the addition of the bacterially expressed His₆-tagged amino acid residues 2–223 of mouse IP₃R1 (H(2–223)_{m1}) (supplemental Fig. S1) on the IP₃-binding activity of (224–604)_{m1}. As shown in supplemental Fig. S3 the addition of 100-fold excess (molar ratio) purified H(2–223)_{m1} did not significantly alter the IP₃-binding affinity of (224–604)_{m1}. These results indicate that the suppression of IP₃ binding requires a covalent bond between the suppressor domain and the IP₃-binding core domain.

Functional Difference among the Suppressor Domains of the Three IP₃R Isoforms—We created six chimeric proteins composed of a suppressor domain fused with an IP₃-binding core domain from different isoforms (supplemental Fig. S1B) to analyze the mechanism underlying the generation of isoform-specific IP₃-binding affinity. All of the equilibrium IP₃ binding data obtained for these chimeric proteins showed good fits with the Hill-Langmuir equation (Equation 1, data not shown) with apparent dissociation constants of 44.2 ± 13.4 nM (*n* = 3) for (1–223)_{m2}-(224–604)_{m1}, 73.0 ± 17.3 nM (*n* = 3) for (1–224)_{m3}-(224–604)_{m1}, 15.8 ± 3.6 nM (*n* = 3) for (1–223)_{m1}-(224–604)_{m2}, 40.7 ± 2.6 nM (*n* = 3) for (1–224)_{m3}-(224–604)_{m2}, 65.9 ± 7.4 nM (*n* = 9) for (1–223)_{m1}-(225–604)_{m3}, and 53.7 ± 5.2 nM (*n* = 3) for (1–223)_{m2}-(225–604)_{m3} (mean ± S.D.). The results of the statistical analyses of these data are shown in Fig. 3. All of the chimeric proteins showed >10-fold lower IP₃-binding affinity (Fig. 3, A–C) compared with the proteins that do not possess the suppressor domain (*K_d* ≈ 2 nM) (Fig. 2). The artificial chimeric proteins, however, revealed apparent dissociation constants that significantly differed from those of the proteins composed of the native combination of the suppressor domain and the IP₃-binding core domain (Fig. 3, A–C). This suggests that the suppressor domain alone is not a prime determinant of the affinity for IP₃. When we compare the same data in respect of the IP₃-binding core domain (Fig. 3, D–F), the different character of the IP₃-binding core domain of the three isoforms became obvious. The IP₃-binding core domain of the type-1 isoform exhibited an almost identical IP₃-binding affinity despite the type of the suppressor domain connected (Fig. 3D). The type-2 IP₃-binding core domain showed indistinguishable affinity for IP₃ when it was fused with the type-1 and type-2 suppressor domains, but the chimeric protein with the type-3 suppressor domain showed an affinity ~3-fold lower compared with the native combination of the type-2 isoform (Fig. 3E). The IP₃-binding core domain of the type-3 isoform strictly required the type-3 suppressor domain to generate its native IP₃-binding affinity (Fig. 3F). These results indicate that: 1) the isoform-specific IP₃-binding affinity is predominantly determined by the IP₃-binding core domain rather than the suppressor domain; 2) the suppressor domains of the type-1 isoform and type-2 isoform are mutually interchangeable for both the IP₃-binding core domains of IP₃R1 and IP₃R2 to generate their native IP₃-binding affinity; and 3) the type-3-specific site(s) in the suppressor domain may be critical for the proper suppression of the IP₃-binding core domain of IP₃R3.




FIGURE 4. IP₃-binding activity of a mutant protein in which all of type-3-specific amino acid residues within the β -strands of the suppressor domain were replaced with those appearing in IP₃R1. A, three-dimensional structure of the suppressor domain of mouse IP₃R1. Twelve β -strands and eleven loop regions are shown in red and blue, respectively. Boundaries of the β -strands and loop regions are determined as described previously (7). B, equilibrium IP₃-binding activity of (β 1, β 4, β 8, β 9, β 12)_{m1}/T604_{m3} (*n* = 3, closed circle), T604_{m3} (open diamond), (1–223)_{m1}-(225–604)_{m3} (open circle), and (225–604)_{m3} (open triangle) is shown. Error bars correspond to the standard deviation.

Critical Loop Regions in the Suppressor Domain for the Suppression of IP₃R3—To elucidate the structural basis for the suppression of the type-3 isoform, we created a series of mutated proteins based on the amino acid sequence difference between IP₃R1 and IP₃R3 and on the three-dimensional structure of the suppressor domain of IP₃R1 (supplemental Fig. S2). The suppressor domain forms a hammer-like structure with the head subdomain and the arm subdomain (7). The head subdomain consists of two single-turn α -helices and 12 β -strands, which form a β -trefoil fold (7). The arm subdomain is made of a helix-turn-helix structure, which is inserted between the fourth and fifth β -strands of the head subdomain (7). We hypothesized that the critical regions for the suppression of the type-3 isoform are located within the 11 loop segments that connect β -strands (Figs. 4A and S2), because in the case of β -trefoil fold architecture most of the surface properties are dictated by the residues from the loop segment, rather than the residues comprising the barrel and the triangular array of the core structure (15). To evaluate this hypothesis, we first constructed a mutant protein in which all of the non-conserved amino acid residues within the β -strand regions of T604_{m3} were substituted with

Isoform-specific IP₃-binding Affinity of IP₃R₃




FIGURE 5. Identification of the loop regions critical for the suppression of IP₃ binding to the type-3 IP₃-binding core domain. *A*, apparent dissociation constants of (1–223)_{m1}-(225–604)_{m3} (lane 1), T604_{m3} (lane 2), L1_{m1}/T604_{m3} (lane 3), L3_{m1}/T604_{m3} (lane 4), L4_{m1}/T604_{m3} (lane 5), L5_{m1}/T604_{m3} (lane 6), L7_{m1}/T604_{m3} (lane 7), L8_{m1}/T604_{m3} (lane 8), and L10_{m1}/T604_{m3} (lane 9). *B*, apparent dissociation constants of (1–223)_{m1}-(225–604)_{m3} (lane 1), T604_{m3} (lane 2), and (L5,L7)_{m1}/T604_{m3} (lane 3). *C*, apparent dissociation constants of (1–223)_{m1}-(225–604)_{m3} (lane 1), (L1,L5,L7)_{m1}/T604_{m3} (lane 2), (L3,L5,L7)_{m1}/T604_{m3} (lane 3), (L4,L5,L7)_{m1}/T604_{m3} (lane 4), (L5,L7,L8)_{m1}/T604_{m3} (lane 5), and (L5,L7,L10)_{m1}/T604_{m3} (lane 6). *D*, apparent dissociation constants of T604_{m3} (lane 1), (L3,L5,L7)_{m3}/(1–223)_{m1}-(225–604)_{m3} (lane 2), and (L5,L7,L8)_{m3}/(1–223)_{m1}-(225–604)_{m3} (lane 3). The number of measurements is shown in parentheses. * $p < 0.05$; ** $p < 0.01$; N.S., not significant (Student's *t* test). The mutants used in this study are summarized in supplemental Fig. S2.

residues appearing in IP₃R1 (supplemental Fig. S2). Non-conserved residues are located within the first, fourth, eighth, ninth, and twelfth β -strand regions (β 1, β 4, β 8, β 9, and β 12, respectively, supplemental Fig. S2) (7). The mutant protein, (β 1, β 4, β 8, β 9, β 12)_{m1}/T604_{m3}, exhibited an apparent dissociation constant of 254.0 ± 48.5 nM ($n = 3$), which was indistinguishable from that of T604_{m3} (163.0 ± 44.4 nM) ($n = 9$) (Fig. 4B). These results indicate that the critical sites for type-3-specific suppression are located within the loop regions, but not within the β -strand regions, of the suppressor domain. Type-3-specific amino acid sequences are located within the first, third, fourth, fifth, seventh, eighth, and tenth loop regions (L1, L3, L4, L5, L7, L8, and L10, respectively, supplemental Fig. S2) (7).

To identify critical sites within the suppressor domain for the suppression of IP₃ binding to the type-3 IP₃-binding core domain, we created seven mutant proteins in which the amino acid sequences of individual type-3-specific loop regions, L1, L3, L4, L5, L7, L8, and L10, were substituted with residues appearing in IP₃R1 (supplemental Fig. S2). We found that both L5_{m1}/T604_{m3} (97.4 ± 26.2 nM, $n = 7$) and L7_{m1}/T604_{m3} (105.0 ± 7.8 nM, $n = 6$) exhibited an apparent dissociation constant, which was significantly different from that of T604_{m3} (Fig. 5A). These results showed that both L5 and L7 are required for the suppression of IP₃ binding to the IP₃-binding core domain of IP₃R3. We then constructed a mutant protein in which type-3-

specific amino acid residues within both L5 and L7 in T604_{m3} were simultaneously changed to the residues that appear in IP₃R1 (supplemental Fig. S2). This mutant protein, (L5,L7)_{m1}/T604_{m3}, exhibited an apparent dissociation constant (80.6 ± 9.9 nM, $n = 6$) that was lower than those of L5_{m1}/T604_{m3} and L7_{m1}/T604_{m3} (Fig. 5B), but the effect of the simultaneous replacement was not statistically significant when compared with the effects of the single loop replacements. The apparent dissociation constant of (L5,L7)_{m1}/T604_{m3} is significantly different from that of (1–223)_{m1}-(225–604)_{m3} (Fig. 5B). We then created five mutant proteins, (L1,L5,L7)_{m1}/T604_{m3}, (L3,L5,L7)_{m1}/T604_{m3}, (L4,L5,L7)_{m1}/T604_{m3}, (L5,L7,L8)_{m1}/T604_{m3}, and (L5,L7,L10)_{m1}/T604_{m3}, in which the type-3-specific amino acid residues in three loop regions, including L5 and L7, were substituted with residues appearing in IP₃R1 (supplemental Fig. S2). Among these mutants, (L3,L5,L7)_{m1}/T604_{m3} and (L5,L7,L8)_{m1}/T604_{m3} exhibited an apparent dissociation constant (69.2 ± 10.6 nM ($n = 5$) and 77.4 ± 12.7 nM ($n = 5$), respectively) that was not different significantly from

that of (1–223)_{m1}-(225–604)_{m3} ($p = 0.525$ and 0.066 , respectively, Fig. 5C). To confirm these results, we created mutant proteins in which all of the type-1-specific amino acid residues within L3, L5, and L7 in (1–223)_{m1}-(225–604)_{m3} or within L5, L7, and L8 in (1–223)_{m1}-(225–604)_{m3} were substituted with residues appearing in IP₃R3 (supplemental Fig. S2). The mutants, (L3,L5,L7)_{m3}/(1–223)_{m1}-(225–604)_{m3} and (L5,L7,L8)_{m3}/(1–223)_{m1}-(225–604)_{m3}, exhibited an apparent dissociation constant of 149.0 ± 5.8 nM ($n = 6$) and 158.0 ± 11.5 nM ($n = 6$), respectively, both of which are indistinguishable from that of T604_{m3} (Fig. 5D). We therefore concluded that L5 and L7 plus either L3 or L8 in the suppressor domain are essential and sufficient for the generation of type-3-specific IP₃-binding affinity of the IP₃-binding core domain of IP₃R3.

Type-3-specific Amino Acid Residues Critical for the Suppression of IP₃ Binding to the Type-3 IP₃-binding Core Domain— Fig. 6 shows amino acid sequence alignments of L3, L5, L7, and L8 of the suppressor domain of the three IP₃R types. The amino acid residues specific for IP₃R3, but not for IP₃R1, are Glu-39, Ala-41, and Asp-46 in L3, Met-127 in L5, Ala-154, Thr-155, and Leu-162 in L7, and Trp-168, Asn-173, Asn-176, and Val-179 in L8 (Fig. 6). All of the amino acid residues except Leu-162 are located at the surface of the suppressor domain of IP₃R3 (Fig. 7).

Loop3				
IP3R1	39	VQPEAGDLNPPKKFRDCL	57	
IP3R2	39	VHPEAGDLANPPKKFRDCL	57	
IP3R3	38	VEPAAGDLNPPKKFRDCL	56	
Loop5				
IP3R1	126	LKSNK	130	
IP3R2	126	IKSNK	130	
IP3R3	127	MKSNK	129	
Loop7				
IP3R1	152	DEAGNEGSWF	161	
IP3R2	152	DAAGNEGSWF	161	
IP3R3	153	DATGNEGSWL	162	
Loop8				
IP3R1	167	YKLSIGDSVIGD	180	
IP3R2	167	WKLRSEGDNIIVGD	180	
IP3R3	168	WKLRNNGDNIIVGD	181	

FIGURE 6. Amino acid sequence alignments of the third, fifth, seventh, and eighth loop regions of the suppressor domain. Amino acid residues identified to be critical for the suppression of IP₃ binding to type-3-IP₃-binding core domain are shown in red. Type-2-unique residues are shown in blue.

DISCUSSION

The IP₃ sensitivity of the intracellular Ca²⁺ stores seems to be heterogenous within the cytosol, and spatially restricted Ca²⁺ releases, such as Ca²⁺ puffs, have frequently been observed in various cell types (16, 17). Multiple intracellular Ca²⁺ stores with variable IP₃ sensitivities in single cells may contribute to the generation of the complex spatiotemporal patterns of intracellular Ca²⁺ dynamics (18–21). We have previously reported that three isoforms of the IP₃R have different IP₃-binding affinities and cooperativities (5). A non-cooperative IP₃ binding model did not fit the equilibrium IP₃ binding data obtained from tetrameric IP₃R2 or IP₃R3 complexes expressed in Sf9 cells (5), indicating that the IP₃-binding affinity of vacant subunits within single tetrameric complexes changes depending on the number of occupied subunits within a homotetrameric complex composed of IP₃R2 or IP₃R3. The intrinsic IP₃-binding affinities, that is the IP₃-binding affinities of four vacant subunits within single non-liganded homotetrameric complexes, have been estimated to be $3.5 \times 10^7 \text{ M}^{-1}$ for IP₃R1, $1.7 \times 10^8 \text{ M}^{-1}$ for IP₃R2, and $3.4 \times 10^6 \text{ M}^{-1}$ for IP₃R3 (5). In the present study, we analyzed the molecular basis of the isoform-specific intrinsic IP₃-binding affinity of IP₃R. The amino-terminal 604 amino acid residues of the three isoforms exhibited almost the same IP₃-binding affinities with the intrinsic IP₃-binding affinities estimated from full-length IP₃Rs expressed in Sf9 cells (Fig. 1). These results indicate that the intrinsic IP₃-binding affinity of homotetrameric IP₃R channels is predominantly determined by the amino-terminal 604 amino acid residues of each subunit. The amino-terminal 225 residues have been known to reduce the IP₃-binding affinity of the IP₃-

binding core domain of IP₃R1 by >10-fold (6), and the deletion of the amino-terminal 225 residues has been reported to enhance the IP₃-binding activity of IP₃R3 (22); however, the effect of the suppressor domain on the affinity of the IP₃-binding core domain has never been quantitatively characterized for type-2 and type-3 isoforms. We measured the IP₃-binding affinity of residues 224–604 of IP₃R2 and residues 225–604 of IP₃R3 and found that both proteins showed an IP₃-binding affinity higher than those obtained for residues 1–604 of IP₃R2 and IP₃R3 by 9.3- and 81.1-fold, respectively (Fig. 2). Interestingly, in the absence of the suppressor domain, all three isoforms exhibit a nearly identical IP₃-binding affinity (Fig. 2). Because Bultynck *et al.* (23) has shown that the suppressor domain of IP₃R1 (residues 1–225) can physically interact with the IP₃-binding core domain of IP₃R1 (residues 226–604), the interdomain interaction may cause changes in the IP₃-binding affinity of the IP₃-binding core domain. The amino-terminal 604 residues of three IP₃R types bind IP₃ in a non-cooperative manner (Fig. 1B), indicating that the suppression of IP₃ binding occurs independently in each molecule. Because the addition of a 100-fold excess of the suppressor domain did not significantly alter the IP₃-binding affinity of the IP₃-binding core domain (supplemental Fig. S3), the suppressor domain is not effective for separating molecules. We therefore suspect that the suppression of IP₃ binding is an intramolecular event that requires a covalent bond between the suppressor domain and the IP₃-binding core domain. The present results suggest that 1) the isoform-specific IP₃-binding affinity originates from the intramolecular suppression of IP₃ binding, but not from the difference in the intrinsic IP₃-binding affinity of the IP₃-binding core domain, and 2) the nature of the interaction between the suppressor domain and the IP₃-binding core domain is different among the three isoforms, thereby resulting in their different IP₃-binding affinities. In other words, the IP₃-binding affinity of IP₃Rs is generated by the precisely controlled attenuation of IP₃-binding affinity caused by the intramolecular interaction between the suppressor domain and the IP₃-binding core domain, and the IP₃-binding affinity is a tunable parameter rather than a stable constant.

Molecular Basis of the Type-specific Suppression of IP₃ Binding—To test domain compatibility among the three IP₃R types, we have engineered chimeric proteins in which the amino-terminal suppressor domain was fused to the IP₃-binding core domain from different isoforms and found that the suppressor domain is not a prime determinant of the IP₃-binding affinity (Fig. 3, A–C). The IP₃-binding core domain of IP₃R1 showed almost the same apparent dissociation constants regardless of the type of the suppressor domain connected (Fig. 3D). The IP₃-binding core domain of IP₃R2 did not discriminate the suppressor domain from IP₃R1 and IP₃R2, but the suppressor domain from IP₃R3 failed to produce the native IP₃-binding affinity of IP₃R2 (Fig. 3E). The IP₃-binding core domain of IP₃R3 strictly required the suppressor domain from the same isoform to produce its native IP₃-binding affinity (Fig. 3F). These results indicate that 1) conserved amino acid residues in the suppressor domain of IP₃R1 and IP₃R2 are involved in the interaction with the type-1 and type-2 IP₃-binding core do-

Isoform-specific IP₃-binding Affinity of IP₃Rs




FIGURE 7. Surface and ribbon diagram representations of critical sites for the IP₃ binding suppression. Surface (A and C) and ribbon diagram (B and D) representations of the suppressor domain of mouse IP₃R1 and surface (E and G) and ribbon diagram (F and H) representations of the suppressor domain of mouse IP₃R3 are shown. The amino acid residues critical for the type-specific suppression are depicted in red. The conserved amino acid residues essential for the IP₃ binding suppression (7) are labeled in pink. Amino acid residues in blue are involved in the determination of the IP₃-binding affinity of IP₃R1 (7). C, view in A rotated by 180°. D, view in B rotated by 180°. G, view in E rotated by 180°. H, view in F rotated by 180°.

mains, and 2) type-3-specific amino acid residues are strictly required for the proper interaction with the type-3 IP₃-binding core domain. Type-3-specific residues may also interfere in the proper interaction with the type-2 IP₃-binding core domain.

IP₃ binding. One possible interpretation is that one of the complexes employs an interface formed by L3, L5, and L7 on the suppressor domain, whereas the other uses an interface formed by L5, L7, and L8. The amino acid sequences of these critical loops might also indirectly affect the structure of the interface

Identification of Amino Acid Residues Critical for the Type-3-specific IP₃-binding Affinity—Systematic mutagenesis analyses (Figs. 4 and 5) showed that at least L5 and L7 in the suppressor domain are essential for the generation of the type-3-specific IP₃-binding affinity. Interestingly, (L3,L5,L7)_{m1}/T604_{m3} and (L5,L7,L8)_{m1}/T604_{m3} exhibited an apparent dissociation constant indistinguishable from that of (1–223)_{m1}-(225–604)_{m3} (Fig. 5C) and (L3,L5,L7)_{m3}/(1–223)_{m1}-(225–604)_{m3} and (L5,L7,L8)_{m3}/(1–223)_{m1}-(225–604)_{m3} exhibited an apparent dissociation constant indistinguishable from that of T604_{m3} (Fig. 5D). These results suggest that, in addition to L5 and L7, either L3 or L8 is required for the generation of the native IP₃-binding affinity of IP₃R3. This interpretation seems to be supported by the results shown in Fig. 5A. The replacement of either L5 or L7 from T604_{m3} resulted in a significant enhancement of the IP₃-binding affinity, whereas, single replacement of either L3 or L8 did not result in a significant alteration of the IP₃-binding affinity (Fig. 5A). The position of L5 and L7 are relatively close on the suppressor domain and the three type-3-specific amino acid residues, Met-127, Ala-154, and Thr-155, within these regions are nearby the previously identified conserved residues essential for the suppression of IP₃ binding to IP₃R1 (Fig. 7). L3 is located on the same side of L5 and L7 on the suppressor domain, whereas L8 is placed on the opposite side (Fig. 7). These results predict a dynamic nature of the intramolecular interaction for the suppression of IP₃ binding. More specifically, there are at least two different conformational states of the complex comprising the suppressor domain and IP₃-binding core domain with both states contributing toward the suppression of

between the suppressor domain and the IP₃-binding domain. According to the prediction, the essential amino acid residues for the generation of the type-3 receptor-specific IP₃-binding affinity are Glu-39, Ala-41, Asp-46, Met-127, Ala-154, Thr-155, Leu-162, Trp-168, Asn-173, Asn-176, and Val-179 (Figs. 6 and 7). Szlufcik *et al.* showed that the deletion of amino acid residues 76–86 of IP₃R1 or the replacement of these residues by residues 75–86 of IP₃R3 resulted in an increase in IP₃ binding and the sensitivity of IP₃-induced Ca²⁺ release (22). In our experiments, the replacement of L4, which includes residues 76–86 of IP₃R1 or residues 75–86 of IP₃R3, did not induce a significant change in the apparent dissociation constant of T604_{m3} (Fig. 5A). Because Szlufcik *et al.* (22) measured the amount of [³H]IP₃ bound to crude membrane fractions prepared from cell lines with different expression levels of recombinant receptors, it is not clear whether the mutations on residues 76–86 significantly affected the IP₃-binding affinity of the actual receptor proteins. Because our results reported here are mainly based on an analysis of the IP₃-binding domain fragments expressed in bacteria, the critical sites for determining isoform-specific IP₃-binding affinity in full-length receptor proteins should be confirmed. Identification of the interface between the suppressor domain and the IP₃-binding core domain by x-ray or NMR analyses should help our better understanding of the nature of the molecular interaction between these two domains.

A Possible Mechanism for the Suppression of IP₃ Binding—Addition of 100-fold excess of the type-1 suppressor domain did not result in a significant reduction of the IP₃-binding affinity of the type-1 IP₃-binding core domain (supplemental Fig. S3). This result indicates that the suppression of IP₃ binding is not a simple competitive inhibition of IP₃ binding to the IP₃-binding core domain by the suppressor domain. Recently, we have measured the reaction kinetics of the fluorescence resonance energy transfer of the IP₃ sensor protein upon the IP₃ binding (24). The IP₃ sensor protein, designated IRIS, is composed of the type-1 IP₃-binding core domain fused to two fluorescent proteins, enhanced cyan fluorescent protein and Venus. Analysis of the reaction kinetics of IRIS shows that there are at least two conformational states of the IP₃-binding core domain in the absence of IP₃ and that IP₃ binding fixes the conformation of the IP₃-binding core domain to one state (24). This reaction model is consistent with the result of the NMR studies, which suggests a dynamic equilibrium exists between two or more conformations in the apo state of the IP₃-binding core domain (25). According to this model, not only the rate constants for ligand-association and dissociation but also the rate constants for conformational changes of the receptor protein determine the equilibrium dissociation constant between the receptor and ligand. Evaluation of the effect of the suppressor domain on the rate of ligand binding and the rate of conformational changes of the IP₃-binding domain should help us to understand the mechanism of the IP₃ binding suppression.

Functional Significance of the Intramolecular Turning of IP₃-binding Affinity—What is the functional significance of the intramolecular attenuation of the intrinsic IP₃-binding affinity of IP₃Rs except for the generation of the isoform-specific IP₃-binding affinity? We have previously shown that the IP₃ binding

to the tetrameric complex of IP₃R2 or IP₃R3 is not a random process, and the occupation of the IP₃-binding site changes the IP₃-binding affinity of vacant sites on the neighboring subunits (5). During the sequential binding of four IP₃ molecules to single tetrameric complexes of IP₃R2 and IP₃R3, the dissociation constants of vacant sites are estimated to be changed to 5.8 × 10⁻⁹ M (0 IP₃ molecule/tetramer), 3.7 × 10⁻⁸ M (1 IP₃ molecule/tetramer), 1.3 × 10⁻⁶ M (2 IP₃ molecules/tetramer), and 3.4 × 10⁻⁷ M (3 IP₃ molecules/tetramer) for IP₃R2 and to 2.9 × 10⁻⁷ M (0 IP₃ molecule/tetramer), 7.0 × 10⁻⁷ M (1 IP₃ molecule/tetramer), 8.2 × 10⁻⁷ M (2 IP₃ molecules/tetramer), and 2.8 × 10⁻⁶ M (3 IP₃ molecules/tetramer) for IP₃R3, respectively (5). These flexible changes of IP₃-binding affinity may be generated from the molecular interaction between occupied subunits and vacant subunits within a single tetrameric channel complex through the suppressor domain of vacant subunits. We have also pointed out that the suppressor domain is a focal point for the interaction with various modulatory proteins, including calmodulin, CaBP1, and RACK1 (7). These proteins may have some potential for the modulation of the IP₃-binding affinity of IP₃Rs by changing the degree of the suppression of IP₃ binding. Our recent analysis of cytosolic IP₃ dynamics in single living cells suggest that IP₃ sensitivity of the intracellular Ca²⁺ stores continuously change during Ca²⁺ oscillations (24). The unique ligand binding machinery, composed of the suppressor domain and the IP₃-binding core domain of IP₃Rs, may account for the generation of the dynamic change of the sensitivity of the receptor for IP₃ in living cells.

Acknowledgments—We thank Dr. Haruka Yamazaki for technical help and Drs. Anita Aperia, Per Uhlen, and Fumio Yoshikawa for fruitful discussions.

REFERENCES

1. Furuichi, T., Kohda, K., Miyawaki, A., and Mikoshiba, K. (1994) *Curr. Opin. Neurobiol.* **4**, 294–303
2. Monkawa, T., Miyawaki, A., Sugiyama, T., Yoneshima, H., Yamamoto-Hino, M., Furuichi, T., Saruta, T., Hasegawa, M., and Mikoshiba, K. (1995) *J. Biol. Chem.* **270**, 14700–14704
3. Newton, C. L., Mignery, G. A., and Sudhof, T. C. (1994) *J. Biol. Chem.* **269**, 28613–28619
4. Nerou, E. P., Riley, A. M., Potter, B. V., and Taylor, C. W. (2001) *Biochem. J.* **355**, 59–69
5. Iwai, M., Tateishi, Y., Hattori, M., Mizutani, A., Nakamura, T., Futatsugi, A., Inoue, T., Furuichi, T., Michikawa, T., and Mikoshiba, K. (2005) *J. Biol. Chem.* **280**, 10305–10317
6. Yoshikawa, F., Morita, M., Monkawa, T., Michikawa, T., Furuichi, T., and Mikoshiba, K. (1996) *J. Biol. Chem.* **271**, 18277–18284
7. Bosanac, I., Yamazaki, H., Matsu-ura, T., Michikawa, T., Mikoshiba, K., and Ikura, M. (2005) *Mol. Cell* **17**, 193–203
8. Bosanac, I., Alattia, J. R., Mal, T. K., Chan, J., Talarico, S., Tong, F. K., Tong, K. I., Yoshikawa, F., Furuichi, T., Iwai, M., Michikawa, T., Mikoshiba, K., and Ikura, M. (2002) *Nature* **420**, 696–700
9. Yoshikawa, F., Uchiyama, T., Iwasaki, H., Tomomori-Satoh, C., Tanaka, T., Furuichi, T., and Mikoshiba, K. (1999) *Biochem. Biophys. Res. Commun.* **257**, 792–797
10. Horton, R. M., Hunt, H. D., Ho, S. N., Pullen, J. K., and Pease, L. R. (1989) *Gene (Amst.)* **77**, 61–68
11. Thompson, J. D., Higgins, D. G., and Gibson, T. J. (1994) *Nucleic Acids Res.* **22**, 4673–4680
12. Sali, A., and Blundell, T. L. (1993) *J. Mol. Biol.* **234**, 779–815

Isoform-specific IP_3 -binding Affinity of IP_3 Rs

13. Koradi, R., Billeter, M., and Wuthrich, K. (1996) *J. Mol. Graph.* **14**, 51–55
14. Yoshikawa, F., Iwasaki, H., Michikawa, T., Furuichi, T., and Mikoshiba, K. (1999) *J. Biol. Chem.* **274**, 328–334
15. Murzin, A. G., Lesk, A. M., and Chothia, C. (1992) *J. Mol. Biol.* **223**, 531–543
16. Bootman, M. D., and Berridge, M. J. (1995) *Cell* **83**, 675–678
17. Parker, I., Choi, J., and Yao, Y. (1996) *Cell Calcium* **20**, 105–121
18. Bootman, M. D., Berridge, M. J., and Taylor, C. W. (1992) *J. Physiol.* **450**, 163–178
19. Taylor, C. W. (1992) *Adv. Second Messenger Phosphoprotein Res.* **26**, 109–142
20. Berridge, M. J., and Dupont, G. (1994) *Curr. Opin. Cell Biol.* **6**, 267–274
21. Marchant, J., Callamaras, N., and Parker, I. (1999) *EMBO J.* **18**, 5285–5299
22. Szlufcik, K., Bultynck, G., Callewaert, G., Missiaen, L., Parys, J. B., and De Smedt, H. (2006) *Cell Calcium* **39**, 325–336
23. Bultynck, G., Szlufcik, K., Kasri, N. N., Assefa, Z., Callewaert, G., Missiaen, L., Parys, J. B., and De Smedt, H. (2004) *Biochem. J.* **381**, 87–96
24. Matsu-ura, T., Michikawa, T., Inoue, T., Miyawaki, A., Yoshida, M., and Mikoshiba, K. (2006) *J. Cell Biol.* **173**, 755–765
25. Bosanac, I., Michikawa, T., Mikoshiba, K., and Ikura, M. (2004) *Biochim. Biophys. Acta* **1742**, 89–102